504 related articles for article (PubMed ID: 26928703)
1. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
2. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas.
Papp E; Steib A; Abdelwahab EM; Meggyes-Rapp J; Jakab L; Smuk G; Schlegl E; Moldvay J; Sárosi V; Pongracz JE
BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32527872
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous
Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].
Chen L; Yang S; Jiang J; Zhang Y; Feng H; Cao J; Ge X; Xie W
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):584-9. PubMed ID: 27666547
[TBL] [Abstract][Full Text] [Related]
5. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
[TBL] [Abstract][Full Text] [Related]
6. Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment.
Mancini R; Giarnieri E; De Vitis C; Malanga D; Roscilli G; Noto A; Marra E; Laudanna C; Zoppoli P; De Luca P; Affuso A; Ruco L; Di Napoli A; Mesiti G; Aurisicchio L; Ricci A; Mariotta S; Pisani L; Andreetti C; Viglietto G; Rendina EA; Giovagnoli MR; Ciliberto G
PLoS One; 2011; 6(7):e21320. PubMed ID: 21789168
[TBL] [Abstract][Full Text] [Related]
7. Survival of lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
9. Prediction of chemotherapeutic response in unresectable non-small-cell lung cancer (NSCLC) patients by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium (MTS) assay.
Chen J; Cheng GH; Chen LP; Pang TY; Wang XL
Asian Pac J Cancer Prev; 2013; 14(5):3057-62. PubMed ID: 23803079
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
[TBL] [Abstract][Full Text] [Related]
11. Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.
Ruiz C; Kustermann S; Pietilae E; Vlajnic T; Baschiera B; Arabi L; Lorber T; Oeggerli M; Savic S; Obermann E; Singer T; Rothschild SI; Zippelius A; Roth AB; Bubendorf L
PLoS One; 2016; 11(8):e0160807. PubMed ID: 27548442
[TBL] [Abstract][Full Text] [Related]
12. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
13. Mutant KRAS promotes malignant pleural effusion formation.
Agalioti T; Giannou AD; Krontira AC; Kanellakis NI; Kati D; Vreka M; Pepe M; Spella M; Lilis I; Zazara DE; Nikolouli E; Spiropoulou N; Papadakis A; Papadia K; Voulgaridis A; Harokopos V; Stamou P; Meiners S; Eickelberg O; Snyder LA; Antimisiaris SG; Kardamakis D; Psallidas I; Marazioti A; Stathopoulos GT
Nat Commun; 2017 May; 8():15205. PubMed ID: 28508873
[TBL] [Abstract][Full Text] [Related]
14. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
Tissot C; Gay P; Brun C; Froudarakis ME
Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
[TBL] [Abstract][Full Text] [Related]
15. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
17. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
[TBL] [Abstract][Full Text] [Related]
18. Feasibility Technique of Low-passage
Vinayanuwattikun C; Prakhongcheep O; Tungsukruthai S; Petsri K; Thirasastr P; Leelayuwatanakul N; Chanvorachote P
Anticancer Res; 2019 Dec; 39(12):6981-6988. PubMed ID: 31810970
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Kubo A; Koh Y; Kawaguchi T; Isa S; Okamoto I; Fukuoka J; Kusunoki Y; Kitaichi M; Takada M; Nakagawa K
Intern Med; 2011; 50(7):745-8. PubMed ID: 21467709
[TBL] [Abstract][Full Text] [Related]
20. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
